<DOC>
	<DOCNO>NCT01527383</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass safety tolerability V212 administer adult autoimmune disease .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Inactivated Varicella Zoster Virus ( VZV ) Vaccine Adults With Autoimmune Disease ( V212-009 )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter study evaluate safety immunogenicity V212 vaccine adult autoimmune disease , include patient rheumatoid arthritis , psoriatic arthritis , psoriasis , inflammatory bowel disease , systemic lupus erythematosus , multiple sclerosis , similar disease .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosed autoimmune disease Clinically stable disease least 30 day enrollment Not likely undergo hematopoietic stem cell transplantation study period Receiving least one parenteral oral biologic agent , TNF alpha inhibitor , parenteral oral nonbiologic therapy , stable dose least 3 month , plan anticipated change History varicella , antibody VZV , residence least 30 year country endemic VZV infection , participant le 30 year old , attend primary secondary school country endemic VZV infection Prior history Herpes Zoster ( shingle ) within 1 year enrollment Prior varicella zoster vaccine Active central nervous system lupus erythematosus require therapeutic intervention within 90 day enrollment Prior plan therapy contain rituximab antiCD20 monoclonal antibody 3 month enrollment 28 day postdose 4 Systemic corticosteroid therapy , prednisone , equivalent 40 mg daily time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Shingles</keyword>
</DOC>